

1 **Polygenic risk scores for asthma and allergic disease associate with COVID-19 severity in**
2 **9/11 responders**

3
4 Monika A. Waszczuk, PhD¹, Olga Morozova, PhD², Elizabeth Lhuillier, MD^{3,4}, Anna R.
5 Docherty, PhD^{5,6}, Andrey A. Shabalin, PhD^{5,6}, Xiaohua Yang, MS⁴, Melissa A. Carr, Ms³, Sean
6 A. P. Clouston, PhD⁷, Roman Kotov, PhD⁸, and Benjamin J. Luft, MD^{3,4}

7
8 ¹ Department of Psychology, Rosalind Franklin University of Medicine and Science, North
9 Chicago, IL

10 ² Department of Public Health Sciences, Biological Sciences Division, University of Chicago,
11 Chicago, IL

12 ³ World Trade Center Health and Wellness Program, Stony Brook University, Stony Brook, NY

13 ⁴ Department of Medicine, Stony Brook University, Stony Brook, NY

14 ⁵ Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT

15 ⁶ Huntsman Mental Health Institute, Salt Lake City, UT

16 ⁷ Program in Public Health, Department of Family, Population, and Preventive Medicine, Stony
17 Brook University, Stony Brook, NY

18 ⁸ Department of Psychiatry, Stony Brook University, Stony Brook, NY

19

20

21 **Corresponding author:**

22 Benjamin J. Luft, MD

23 Email: Benjamin.Luft@stonybrookmedicine.edu

24 **ORCID IDs:**

25 Monika A. Waszczuk: 0000-0003-1775-1970

26 Olga Morozova: 0000-0001-7606-8413

27 Anna R. Docherty: 0000-0001-7139-7007

28 Andrey A. Shabalin: 0000-0003-0309-6821

29 Melissa Carr: 0000-0002-0870-6628

30 Roman Kotov: 0000-0001-9569-8381

31 Benjamin J. Luft: 0000-0001-9008-7004

32

33 **Abstract:** 198 words

34 **Manuscript:** 3,514 words

35 **Tables:** 4

36 **References:** 29

37

38

39 Abstract

40 **Background.** Genetic factors contribute to individual differences in the severity of coronavirus
41 disease 2019 (COVID-19). A portion of genetic predisposition can be captured using polygenic
42 risk scores (PRS). Relatively little is known about the associations between PRS and COVID-19
43 severity or post-acute COVID-19 in community-dwelling individuals. **Methods.** Participants in
44 this study were 983 World Trade Center responders infected for the first time with SARS-CoV-2
45 (mean age at infection=56.06; 93.4% male; 82.7% European ancestry). Seventy-five (7.6%)
46 responders were in the severe COVID-19 category; 306 (31.1%) reported at least one post-acute
47 COVID-19 symptom at 4-week follow-up. Analyses were adjusted for population stratification
48 and demographic covariates. **Findings.** The asthma PRS was associated with severe COVID-19
49 category (odds ratio [OR]=1.61, 95% confidence interval: 1.17-2.21) and more severe COVID-
50 19 symptomatology ($\beta=.09$, $p=.01$), independently of respiratory disease diagnosis. Severe
51 COVID-19 category was also associated with the allergic disease PRS (OR=1.97, [1.26-3.07])
52 and the PRS for COVID-19 hospitalization (OR=1.35, [1.01-1.82]). PRS for coronary artery
53 disease and type II diabetes were not associated with COVID-19 severity. **Conclusion.** Recently
54 developed polygenic biomarkers for asthma, allergic disease, and COVID-19 hospitalization
55 capture some of the individual differences in severity and clinical course of COVID-19 illness in
56 a community population.

57

58 **Keywords:** 9/11 responders; COVID-19; SARS-CoV-2; post-acute COVID-19 syndrome;
59 polygenic risk score; asthma; allergic disease

60

61 **Polygenic risk scores for asthma and allergic disease associate with COVID-19 severity in**
62 **9/11 responders**

63 **Introduction**

64 Coronavirus disease 2019 (COVID-19) is caused by an infection by the severe acute respiratory
65 syndrome coronavirus (SARS-CoV-2) and remains a pandemic in the US and globally [1].
66 COVID-19 invades the respiratory and other crucial systems in the body, varying widely in
67 severity, from asymptomatic presentation to severe outcomes including hospitalization or death.
68 Moreover, at least one-third of individuals with COVID-19 develop post-acute COVID-19
69 syndrome [2], which consists of residual respiratory, fatigue, central nervous system, and
70 musculoskeletal symptoms that persist at least four weeks after initial symptom onset [3, 4].
71 Despite vaccination efforts, the potentially severe and chronic outcomes of COVID-19
72 necessitate a better characterization of individuals at elevated risk for clinically significant
73 disease outcomes.

74 Across a range of studies, COVID-19 severity was found to be associated with clinical risk
75 factors such as older age, male sex, smoking, respiratory illness, cardiovascular disease, and
76 immunocompromised status [5-7]. Moreover, a person's own genetic factors critically affect
77 individual differences in COVID-19 disease severity [8]. Large-scale, population-based genome-
78 wide association studies (GWAS) indicate that multiple common genetic variants can contribute
79 to COVID-19 symptom severity after infection [9]. Genes that emerged from GWAS most
80 strongly associated with severe COVID-19 progression are involved in immune response and
81 lung disease pathology. The individual variants associated with disease severity in the discovery
82 GWAS have minor effects, but cumulatively they explain a substantial proportion of genetic

83 variation in response to the virus. Common variants can be collapsed into a polygenic risk score
84 (PRS) to improve the prediction of at-risk patients in an independent cohort. For each individual,
85 the number of risk alleles carried at each variant (0, 1, or 2) can be summed and weighted by its
86 effect size, resulting in a single score of each individual's genetic vulnerability to COVID-19
87 severity.

88 COVID-19 PRS have shown to be associated with increased risk of morbidity and mortality due
89 to COVID-19 in several independent samples and across ancestries, with PRS outperforming
90 individual genetic variants and providing information over and above established risk factors
91 [10-13]. While the COVID-19 PRS was designed to capture all genes associated with the
92 severity of COVID-19, the studies relied partially on the UK Biobank cohort, which has limited
93 phenotypic information on COVID-19 disease and exposure status of controls, largely based on
94 electronic medical records of laboratory test results and ICD-10 codes for COVID-19 and
95 respiratory support. It is therefore plausible that other PRS capture genetic vulnerability to other
96 conditions, such as asthma or coronary artery disease, that might also associate with COVID-19
97 symptom severity or COVID-19 clinical course, although empirical evidence is limited. For
98 example, only one published study has reported no association between asthma PRS and severe
99 COVID-19 [14], but no other studies to our knowledge have examined post-acute COVID-19
100 symptoms.

101 Therefore, the present study translated genetic discoveries in COVID-19 host genetics to an
102 independent, well-characterized patient population with a full range of COVID-19 severity.
103 Responders to the World Trade Center (WTC) attacks on September 11, 2001 are a cohort with
104 detailed prospective health data, including information on COVID-19 infection, symptom
105 severity, and follow-up outcomes. Our team has previously demonstrated that younger and

106 employed responders were at a higher risk of being infected with the SARS-CoV-2 virus [15].
107 Among those who experienced infection, a pre-existing obstructive airway disease diagnosis
108 predicted an elevated risk for a more severe COVID-19 presentation [2]. The risk of developing
109 post-acute COVID-19 sequelae was similarly elevated in responders with respiratory problems
110 as well as heart disease, over and above the risk conferred by the COVID-19 severity itself.
111 While respiratory and other chronic conditions are associated with toxic exposures during the
112 9/11 disaster, some of the individual differences in post-exposure outcomes in 9/11 responders
113 can be attributed to genetic vulnerabilities [16, 17].

114 Relatively little work describing genetic risk to COVID-19 severity has been conducted in
115 community individuals with a full range of symptom severity. The associations between PRS and
116 a common long-term outcome of post-acute COVID-19 also remain unknown. Thus, building on
117 our previous work in the large sample of WTC responders who were infected with SARS-CoV-
118 2, we investigated whether polygenic vulnerabilities to COVID-19 hospitalization, as well as to
119 asthma, related allergic diseases, coronary artery disease, and type II diabetes, were associated
120 with COVID-19 severity and post-acute COVID-19 symptoms, after adjusting for established
121 risk factors. We investigated genetic associations with a full range of COVID-19 symptoms, as
122 well as genetic risk for the severe COVID-19, which has the highest clinical relevance as it
123 includes hospitalized cases. Based on previous findings, we hypothesized that PRS for COVID-
124 19 hospitalization would be significantly associated with COVID-19 severity across a range of
125 symptoms, and would help identify the most severe COVID-19 group. We tentatively
126 hypothesized that PRS for asthma, allergic disease, coronary artery disease, and type II diabetes
127 would be associated with worse COVID-19 severity outcomes and that the polygenic
128 associations would extend to development of post-acute COVID-19 sequelae. We

129 **Methods**

130 **Participants and Procedure**

131 Participants were 983 WTC responders enrolled in a prospective cohort called the WTC Health
132 Program which was established in 2002 and independently monitors the health of more than
133 13,000 WTC first responders living on Long Island, NY, USA [18]. The analytic sample
134 comprised of all genotyped participants from an established cohort of responders with the first
135 instance of SARS-CoV-2 infection before January 2022, with the median infection date of
136 December 2020 [2]. The mean age of the analytic sample at infection was 56.06, $SD=7.37$,
137 $range= 39.79-89.04$, 93.4% of the sample was male, and 82.3% had European ancestry. The
138 analytic sample did not differ significantly from the total cohort of responders with SARS-CoV-
139 2 infection ($N=1,280$) on demographic and symptom variables (all p-values for independent
140 sample t-tests and chi-square tests >0.05).

141 The analytic sample included responders with a verified history of a positive polymerase chain
142 reaction, antigenic, or antibody test for SARS-CoV-2 or positivity for antibodies to SARS-CoV-
143 2 nucleocapsid protein according to medical or laboratory records ($N=587$), as well as
144 responders who reported a positive laboratory test for SARS-CoV-2, but for whom documented
145 proof of the test results was not available ($N=396$). The unverified cases did not differ
146 significantly from verified cases on all study variables, except for lower COVID-19 severity
147 ($t(df)=2.30 (847.60)$, $p=.02$, $d=.15$). Verifiable hospitalization records at local hospitals increased
148 the likelihood of objectively verifying the most severe responders. Analyses adjusted for
149 verification status. All cases represent a first instance of SARS-CoV-2 infection.

150 Clinical information on initial and residual COVID-19 symptoms was collected irrespective of
151 verification status through in-person questionnaires, surveys sent via email and text, electronic
152 medical records obtained with the release of health information forms, and follow-up calls.
153 Symptoms of COVID-19 in this study included respiratory symptoms (i.e., shortness of breath,
154 chest pain, sore throat, congestion/runny nose, and wheezing), systemic symptoms (i.e., fever,
155 fatigue, headache, chills, and weight loss), gastrointestinal symptoms (i.e., nausea, vomiting, and
156 diarrhea), musculoskeletal symptoms (i.e., joint and muscle pain), central nervous system
157 symptoms (i.e., dizziness, vertigo, loss of smell/taste, and brain fog), and psychiatric symptoms
158 (i.e., anxiety, depression, and post-traumatic stress disorder [PTSD]).

159 Blood samples for genotyping were drawn at the WTC Health Program clinic as a routine part of
160 the monitoring examination from January 2012 to January 2019. The study was approved by the
161 Institutional Reviewer Board of Stony Brook University, and all participants provided written
162 informed consent. For more information on the study design, see Lhuillier, Yang [2].

163 **Measures**

164 **COVID-19 severity**

165 Participants in the analytic sample were categorized into four severity groups according to their
166 symptoms: asymptomatic ($N=92$, 9.4%), mild ($N=378$, 38.5%), moderate ($N=408$, 41.5%), and
167 severe ($N=75$, 7.6%). This categorization was based on the NIH COVID-19 clinical spectrum
168 updated October 2021 (National Institutes of Health, 2021). The asymptomatic category
169 consisted of responders who reported a positive SARS-CoV-2 virologic test result without any
170 symptoms associated with COVID-19. The mild category included responders with at least one
171 symptom associated with COVID-19 but no shortness of breath or difficulty breathing. Moderate

172 cases were in responders who reported shortness of breath and/or diagnosis of lower respiratory
173 disease (pneumonia/bronchitis) during clinical assessment or imaging. These responders
174 maintained oxygen saturation (SpO_2) \geq 94% on room air at sea level. Mild and moderate cases
175 were medically managed primarily at home, even if they initially visited a healthcare facility for
176 medical treatment and/or testing. Severe cases included responders with SpO_2 $<$ 93% on room air,
177 respiratory rate $>$ 30 breaths/min, heart rate greater than 100 beats per minute, acute respiratory
178 distress syndrome, septic shock, cardiac dysfunction, or an exaggerated inflammatory response
179 in addition to pulmonary disease, or severe illness causing cardiac, hepatic, renal, central nervous
180 system, or thrombotic disease during COVID-19. Responders were also categorized as severe if
181 they were admitted to the hospital, or received intensive care or mechanical ventilation, or if they
182 eventually died from COVID-19.

183 Two complimentary analytic variables were created: an ordinal COVID-19 severity variable on
184 1-4 scale corresponding to asymptomatic, mild, moderate, and severe symptoms, and a binary
185 COVID-19 severe category variable, with asymptomatic, mild, and moderate patients in one
186 category, and severe patients in the second category.

187 **Post-acute COVID-19 symptoms**

188 Residual symptoms were defined as any COVID-19-related symptoms that lasted at least 4
189 weeks after symptom onset (Centers for Disease Control and Prevention, 2021b). Residual
190 symptoms included respiratory problems (e.g., dyspnea, chest discomfort, cough, and fatigue),
191 CNS symptoms (e.g., loss or reduction of smell/taste, mental fog, dizziness, and vertigo), and
192 musculoskeletal complaints. In the analytic sample, N=306 (31.1%) participants reported at least

193 one residual COVID-19 symptom. A binary analytic variable was created to compare
194 participants with and without at least one residual symptoms.

195 **Covariates**

196 Electronic medical records updated on January 1, 2020, were used to obtain date of birth to
197 calculate age at infection, obstructive airway disease and upper respiratory disease diagnoses,
198 lifetime posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) diagnoses,
199 and the most recent available measure of body mass index (BMI). Obstructive airway disease
200 category includes diagnoses of asthma and bronchitis, upper respiratory disease includes chronic
201 rhinitis and chronic sinusitis [18]. Respiratory diagnoses were determined based on systemic
202 examination by a physician or nurse practitioner and included repeated pulmonary function tests,
203 physical examination, and medical history. BMI scores were analyzed as continuous variable to
204 maximize statistical power [19, 20]. Genetic data were used to obtain sex and ancestry
205 information.

206 **Genetic data processing and polygenic risk scores (PRS)**

207 Genotyping of blood samples was performed at the Genomics Shared Resource at Roswell Park
208 Cancer Institute, using the Infinium Global Screening Array (Illumina, San Diego, CA, USA),
209 according to manufacturer protocols. Genotypes were imputed on the Michigan Imputation
210 Server pipeline v1.2.4, using the Haplotype Reference Consortium reference panel [21]. Before
211 imputation, the genotypes were filtered for ambiguous strand orientation, missingness rate >5%
212 (by marker exclusion, then by individual), Hardy-Weinberg equilibrium violation ($p < 10^{-6}$), and
213 sex mismatch. After imputation, the single-nucleotide polymorphisms (SNPs) were excluded for
214 imputation $R^2 < 0.5$ and the average call rate below 90%. Genotype imputation was performed on

215 552,230 SNPs, resulting in 25,514,638 SNPs after quality control, which were used for matching
216 to discovery GWAS variants for the final polygenic risk scoring.

217
218 PRS were created using PRSice 2.0 [22]. PRS were created by aggregating genetic variants that
219 emerged from the GWAS of the phenotype of interest, i.e. the GWAS discovery sample. Our
220 primary analysis used a complete list of SNPs after clumping, and their corresponding weights
221 from GWAS discovery samples (P-value threshold=1) to incorporate more of the genome [23].
222 All analyses adjusted for the first ten genetic ancestry principal components (PCs). Primary
223 analyses were conducted on participants of European ancestry due to the discovery GWAS being
224 European; however, sensitivity analyses in the entire sample are also reported in the
225 Supplementary Materials.

226 PRS for asthma and allergic disease were based on two GWAS conducted on participants of
227 European ancestry from the UK Biobank [24]. The asthma GWAS was conducted in 90,853
228 individuals, 14,085 physician-diagnosed asthma cases, and 76,768 controls without asthma or
229 allergic diseases. Asthma is heterogeneous phenotype and cases with allergic, non-allergic,
230 mixed, and other forms of asthma were included in GWAS. The allergic disease GWAS was
231 conducted in 102,453 individuals, 25,685 with doctor-diagnosed hay fever, allergic rhinitis,
232 eczema, or allergic asthma cases, and 76,768 controls without asthma or allergic disease.

233 The coronary artery disease PRS was based on a GWAS meta-analysis conducted in 122,733
234 coronary artery disease cases and 424,528 controls from the UK Biobank and the
235 CARDIoGRAMplusC4D Consortium [25]. Cases included patients with coronary artery disease
236 diagnosis or treatment indicated in their electronic medical record or self-reported heart
237 attack/myocardial infarction, coronary angioplasty, or heart bypass. The control group excluded

238 participants who reported that their mother, father, or sibling suffered from heart disease. The
239 type II diabetes PRS was based on a GWAS meta-analysis in 62,892 type II diabetes cases and
240 596,424 controls of European ancestry [26].

241 PRS for COVID-19 severity were based on summary statistics from two GWAS meta-analyses
242 conducted by the COVID-19 Host Genetics Initiative [9] release 6, dated June 15, 2021. This
243 initiative is an international collaboration spanning 61 studies from 24 countries. The first
244 GWAS was performed in 2,085,803 individuals, contrasting 24,274 patients hospitalized due to
245 COVID-19 with 2,061,529 population controls presumed to be COVID-19 negative (COVID-
246 PRS hospitalized vs. population). The second GWAS was conducted in 87,671 patients with
247 COVID-19, contrasting 14,480 hospitalized patients with 73,191 non-hospitalized patients
248 (COVID-PRS hospitalized vs. not-hospitalized).

249 **Analytic approach**

250 Linear regression was used to test whether PRS is associated with ordinal COVID-19 severity.
251 Logistic regression was used to test whether PRS is associated with the severe COVID-19
252 category classification (severe vs. moderate/mild/asymptomatic), and the presence of post-acute
253 COVID-19 symptoms. Continuous variables were standardized prior to analysis by transforming
254 them to Z scores with a mean of zero and standard deviation of one. Models were adjusted for
255 the first ten principal components of the population structure, COVID-19 verification status, age,
256 and sex. Models testing asthma and allergic disease PRS were further adjusted for obstructive
257 airway disease and upper respiratory disease diagnoses to ensure that associations do not merely
258 reflect respiratory illness status. A supplementary analysis further adjusting for PTSD and MDD
259 diagnoses was conducted for asthma PRS, to test the potential role of mental health in the

260 associations. Likewise, models testing PRS for coronary artery disease and type II diabetes
261 further adjusted for BMI. Models testing associations with residual symptoms additionally
262 adjusted for COVID-19 severity. Separate models were conducted for each PRS. The primary
263 analyses were conducted in participants of European ancestry. Given that COVID-19 GWAS
264 were completed using multi-ancestry participants, for sensitivity testing and inclusivity results
265 are also reported for participants of all ancestries in Supplementary Materials. All analyses used
266 nominal p-value threshold $<.05$ and were conducted in SPSS version 28 and R version 4.1.0.

267 **Role of the funding source**

268 The funders had no role in the design of the study, in the collection, analyses, or interpretation of
269 data, in the writing of the manuscript, or in the decision to publish the results.

270 **Results**

271 Descriptive statistics for the European ancestry sample are reported in Table 1. Many responders
272 ($N=57$, 7.0%) had severe COVID-19. In total, 247 (30.4%) responders reported at least one
273 residual COVID-19 symptom. Correlations between PRS are reported in Supplementary Table
274 S1.

275

276 **Table 1 – Descriptive statistics for participants of European ancestry.**

277

N total	813
N male (%)	772 (95.0%)
Mean age at infection (SD), range	56.06 (7.37), 39.79-89.04
N OAD diagnosis (%)	312 (38.4%)
N URD diagnosis (%)	525 (64.6%)
N PTSD and/or MDD diagnosis (%)	124 (15.3%)
Mean BMI (SD), range	31.34 (5.08), 19.48-62.18
N COVID-19 severity (%)	
Asymptomatic	78 (9.6%)
Mild	320 (39.4%)
Moderate	332 (40.8%)
Severe	57 (7.0%)
Missing	26 (3.2%)
N any residual symptoms	247 (30.4%)

278

279 *Notes:*

280 OAD – Obstructive airway disease; URD – upper respiratory disease; PTSD-Posttraumatic stress

281 disorder, MDD – Major depressive disorder, BMI – body mass index; COVID-19 – coronavirus

282 disease 2019; SD - standard deviation.

283

284

285 The PRS for asthma was significantly associated with COVID-19 severity in the European
286 ancestry subsample ($\beta=.09$, $p=.01$), adjusting for co-occurring obstructive airway disease
287 diagnoses and upper respiratory disease diagnoses, Table 2. Likewise, the PRS for asthma was
288 associated with COVID-19 severe category ($OR=1.61$, [1.17-2.21]). Allergic disease PRS
289 showed a similar pattern, significantly associating the COVID-19 severe category ($OR=1.97$,
290 [1.26-3.07]). Associations with residual COVID-19 symptoms were not significant. There were
291 no significant associations between coronary artery disease or type II diabetes PRS, and COVID-
292 19 phenotypes (Table 3). The COVID-19 PRS based on the GWAS contrasting hospitalized
293 cases vs. controls was significantly associated with the COVID-19 severe category in sample
294 with European ancestry ($OR=1.35$, [1.01-1.82]), Table 4. Conversely, the COVID-19 PRS based
295 on the GWAS contrasting hospitalized cases vs. non-hospitalized cases did not reach
296 significance in the European ancestry subsample. Moreover, none of the COVID-19 PRS were
297 associated with the full range of COVID-19 severity, nor the presence of any residual symptoms.
298

299 **Table 2– Associations between allergic disease and asthma PRS and COVID-19 severity**
 300 **and residual symptoms in participants of European ancestry.**

301

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Asthma	$\beta=.09, p=.01$	OR=1.61 (CI: 1.17-2.21), $p<.01$	OR=1.07 (CI: .90-1.27), $p=.43$
PRS: Allergic disease	$\beta=.09, p=.06$	OR=1.97 (CI: 1.26-3.07), $p<.01$	OR=.89 (CI: .70-1.13), $p=.34$

302

303 *Notes:*

304 OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:
 305 coronavirus disease 2019. All models are adjusted for the first ten principal components of the
 306 population structure, verification status, age at infection, sex, obstructive airway disease
 307 diagnosis, upper respiratory disease diagnosis. Models with residual symptoms as a dependent
 308 variable were additionally adjusted for COVID-19 severity. Associations between asthma PRS
 309 and COVID-19 outcomes were not affected by lifetime PTSD and MDD diagnoses, see
 310 Supplementary Table S6.

311

312

313 **Table 3 – Associations between coronary artery disease and type II diabetes PRS and**
314 **COVID-19 severity and residual symptoms in participants of European ancestry.**

315

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: Coronary artery disease	$\beta=.05, p=.21$	$OR=1.06$ (CI: .70-1.60), $p=.79$	$OR=1.22$ (CI: .97-1.53), $p=.09$
PRS: Type II diabetes	$\beta=.04, p=.32$	$OR=1.42$ (CI: .80-2.53), $p=.23$	$OR=.71$ (CI: .50-1.01), $p=.05$

316

317 *Notes:*

318 OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:
319 coronavirus disease 2019. All models are adjusted for the first ten principal components of the
320 population structure, verification status, age at infection, sex, and BMI. Models with residual
321 symptoms as a dependent variable were additionally adjusted for COVID-19 severity.

322

323

324 **Table 4 – Associations between COVID-19 PRS and COVID-19 severity and residual**
 325 **symptoms in participants of European ancestry.**

326

	COVID-19 severity	COVID-19 severe category	Any residual symptoms
PRS: COVID-19 hospitalized vs. controls	$\beta=.03, p=.40$	OR=1.35 (CI: 1.01-1.82), $p=.04$	OR=1.11 (CI: .93-1.33), $p=.24$
PRS: COVID-19 hospitalized vs. not-hospitalized	$\beta=.05, p=.23$	OR=1.27 (CI: .95-1.69), $p=.12$	OR=1.08 (CI:.90-1.29), $p=.41$

327

328 *Notes:*

329 OR: Odds ratio; CI: 95% confidence interval; PRS: polygenic risk score; COVID-19:

330 coronavirus disease 2019. All models are adjusted for the first ten principal components of the

331 population structure, verification status, age at infection, and sex. Models with residual

332 symptoms as a dependent variable were additionally adjusted for COVID-19 severity.

333

334

335

336

337 **Sensitivity analyses**

338 Descriptive statistics for total sample with participants of all ancestries are reported in
339 Supplementary Table S2. In the total sample, adjusting for respiratory disease diagnoses, the
340 PRS for asthma was significantly associated with COVID-19 severity ($\beta=.08$, $p=.01$) and
341 COVID-19 severe category ($OR=1.53$, [1.15-2.03]), and the allergic disease PRS was associated
342 with the COVID-19 severe category ($OR=1.86$, [1.25-2.77]), Supplementary Table S3. There
343 were no significant associations between coronary artery disease or type II diabetes PRS, and
344 COVID-19 phenotypes, Supplementary Table S4. The COVID-19 PRS based on the GWAS
345 contrasting hospitalized cases vs. controls was significantly associated with the COVID-19
346 severe category in the whole sample ($OR=1.42$, [1.11-1.82]), Supplementary Table S5. Likewise,
347 the COVID-19 PRS based on the GWAS contrasting hospitalized cases vs. non-hospitalized
348 cases was also significantly associated with COVID-19 severe category in the total sample
349 ($OR=1.33$, [1.04-1.69]). Accounting for PTSD and MDD diagnoses did not alter associations
350 between asthma PRS and COVID-19 outcomes, see Supplementary Table S6.

351 **Discussion**

352 The current study reports associations between recently developed polygenic biomarkers and
353 COVID-19 severity in a community-based population of responders to the WTC disaster who
354 had COVID-19. We found that the PRS for asthma, allergic diseases, and COVID-19 severity
355 were elevated in the severe COVID-19 category responders.. Asthma PRS was additionally
356 associated with COVID-19 symptomatology across the full spectrum of COVID-19 severity. No
357 significant associations were observed for PRS for coronary artery disease and type II diabetes.
358 Moreover, PRS were not associated with post-acute COVID-19 sequelae. These findings add to

359 the growing body of evidence to suggest that existing polygenetic profiles could be informative
360 about the risk for severe COVID-19 presentation, despite the small effect sizes.

361 The current study is the first to report significant associations between asthma PRS and allergic
362 disease PRS, and COVID-19 severity. A previous study in the UK Biobank found no association
363 between asthma PRS and severe COVID-19 [14]. However, the direction of association was
364 positive, and asthma diagnosis was significantly associated with COVID-19 severity ($OR=1.39$),
365 in line with epidemiological and clinical evidence [7]. In contrast to Zhu, Hasegawa [14], in our
366 subsample with European ancestry, the PRS for asthma was associated with a 1.61-fold increase
367 in the odds of classification into the most severe COVID-19 category, as well as with the full
368 range of COVID-19 symptom severity, independently of respiratory diagnoses. Our focus on
369 patients with a wide range of COVID-19 symptoms, in contrast with Zhu, Hasegawa [14] focus
370 on hospitalized cases with severe COVID-19, might be a strength of the current study that
371 explains different findings. Other potential explanations include demographic differences
372 between the samples, data collection at different phases of the pandemic, and differences in
373 sample sizes.

374
375 Allergic disease PRS based on the related GWAS of cases with doctor-diagnosed hay fever,
376 allergic rhinitis, eczema, or allergic asthma doubled the odds of classification into the most
377 severe COVID-19 category in participants of European ancestry ($OR=1.97$), adjusting for
378 demographic covariates and respiratory diagnoses. Taken together, these results are consistent
379 with the evidence for the role of immune function genes implicated in COVID-19 severity [8]. It
380 is possible that asthma and allergic sensitization contribute to the pathobiology of severe
381 COVID-19, such as expression of the SARS-CoV-2 receptor ACE2 [27, 28], and that asthma and

382 allergic disease PRS capture these effects. Another possibility is that both asthma and atopic
383 disease have a proclivity toward a TH2 immune response and thus may contribute to a TH1 or
384 TH2 imbalance and a poorer outcome [29]. Finally, despite the substantial genetic correlation
385 between asthma and mental health [30], responders' history of PTSD and MDD did not explain
386 the association between asthma PRS and COVID-19 severity.

387
388 Contrary to our hypotheses, PRS for coronary artery disease and type II diabetes were not
389 associated with any COVID-19 outcomes. Cardiovascular and other obesity-related disorders
390 have previously been highlighted as risk factors for severe COVID-19 presentation and residual
391 symptoms [7, 31], including in our sample [2]. However, our findings suggest that genetic
392 vulnerability to these conditions might not contribute prominently to COVID-19 severity. A
393 study found a significant association between BMI PRS and higher risk of severe COVID-19
394 outcomes such as hospitalization; however, the effect sizes were small ($OR=1.14$) [32] and were
395 below effect sizes the present study was powered to detect. Furthermore, the previous study did
396 not find significant relationships between COVID-19 outcomes and PRS for BMI-adjusted
397 waist-to-hip ratio and BMI-adjusted waist circumference, indicating an overall weak association
398 between genetic vulnerability to high weight and COVID-19 severity, consistent with the current
399 findings for PRS developed for coronary artery disease and type II diabetes.

400
401 The PRS based on the largest GWAS to date comparing hospitalized COVID-19 cases to healthy
402 controls [9] was significantly associated with a 1.35-fold increase in the odds of having had
403 severe COVID-19. This finding agrees with previous studies based on large cohorts such as the
404 UK Biobank which found that COVID-19 PRS were associated with severe COVID-19

405 outcomes [10-12]. For example, Nakanishi, Pigazzini [10] reported that COVID-19 PRS
406 predicted death or severe respiratory failure (OR=1.70). Similarly, Horowitz, Kosmicki [11]
407 reported that a PRS based on the top six SNPs associated with COVID-19 predicted a 1.38-fold
408 increased risk of hospitalization and a 1.58-fold increased risk of severe disease in European
409 ancestry participants, with results replicated in other ancestries. Importantly, COVID-19 severity
410 PRS were not associated with the full spectrum of COVID-19 symptoms in our population and
411 did not associate with residual post-acute COVID-19 syndrome. This finding adds novel
412 evidence that the COVID-19 PRS specifically captures genetic vulnerability to a severe response
413 to SARS-CoV-2 infection.

414

415 **Strengths and Limitations**

416 The strengths of the current study include a large sample with well-characterized COVID-19
417 symptomatology, follow-up information on post-acute COVID-19 sequelae, and application of
418 PRS based on the largest discovery samples available for each disease. Nonetheless, we also note
419 several limitations. First, although we demonstrated that genotyped patients did not differ
420 significantly from non-genotyped patients, the specific inclusion and exclusion criteria might
421 result in selection bias, contributing to the broader non-representativeness of the WTC cohort to
422 the general population. The proportion of individuals with ancestry admixture in the WTC
423 cohort is too small to allow genetic analyses in non-Northern European ancestries. Nonetheless,
424 for transparency, we opted to report analyses in the total sample as well as the European ancestry
425 subsample, and results are notably similar. In either sample, we were underpowered to detect
426 very small associations. Relatedly, the WTC responder population is primarily male, and the
427 number of females was insufficient to explore sex differences. Moreover, we were underpowered

428 to stratify the sample by age, respiratory illness, or other characteristics related to COVID-19
429 severity. We have adjusted for these covariates in our analyses, but acknowledge that the
430 findings arising from the current study may not generalize to other populations.

431 Second, some participants were included based on infection information that was not
432 independently verified by the study team. However, these participants reported testing positive
433 for SARS-CoV-2 through one of the available testing methods and did not differ from verified
434 participants on any characteristics except COVID-19 severity, which is due to verified records
435 being available for hospitalized responders, suggesting that misclassification was likely to be
436 minimal. The COVID-19 verification status was included as a covariate in all analyses. Third,
437 different viral strains emerged and vaccination status changed over the course of this study.
438 These factors can affect infection susceptibility and COVID-19 disease severity. For example,
439 COVID-19 vaccines are very effective in lowering infection and disease severity [33, 34], which
440 in turn could decrease the role of host genetics in COVID-19 outcomes, attenuating observed
441 PRS associations. Moreover, in vaccinated individuals, PRS associations with COVID-19
442 severity could instead reflect vulnerability to vaccine breakthroughs. We did not have sufficient
443 data to investigate these issues, which likely have contrasting effects on our results, and limit
444 their comparability to studies conducted at different points in the pandemic. Future studies of
445 PRS are needed to model complex interactions between these factors.

446 Fifth, the current study used asthma PRS based on a GWAS of a broadly defined asthma.
447 However, asthma is a complex and heterogeneous condition, with allergic and non-allergic
448 asthmas demonstrating partially different genetic etiologies [24, 35, 36]. Accordingly, PRS for
449 specific asthma subtypes based on allergy and age-at-onset have been shown to differentially
450 associate with outcomes such as BMI [37]. Thus, future work should replicate and clarify

451 whether observed associations between asthma PRS and COVID-19 severity differ across
452 asthma subtypes.

453 **Conclusions**

454 The current translational study found that PRS for asthma, allergic disease, and COVID-19
455 hospitalization were associated with an increased risk for severe COVID-19 presentation among
456 community-based individuals infected with SARS-CoV-2. Asthma PRS was also associated with
457 higher COVID-19 severity across the full range of COVID-19 symptoms. The current effect
458 sizes were small, but with additional research, known genetic vulnerability factors might help to
459 identify individuals at an increased risk for a severe course of COVID-19 disease.

460

461 **Acknowledgements**

462 We thank participants for their commitment to the project

463 **Funding Source**

464 The study was funded by CDC/NIOSH awards U01OH012275 to Drs. Luft and Morozova, and
465 U01OH011864 to Drs. Waszczuk and Kotov. Additional support was provided by National
466 Institute of Health awards R01MH123619 and R01MH123489 to Drs. Docherty and Shabalin.
467 We would like to acknowledge ongoing funding to monitor World Trade Center responders as
468 part of the WTC Health and Wellness Program (CDC 200-2011-39361). The findings and

469 conclusions in this article are those of the authors and do not represent the official position of
470 CDC.

471 **Conflict of Interest Statement**

472 The authors declare no conflict of interest. The funders had no role in the design of the study; in
473 the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the
474 decision to publish the results.

475 **Data Availability Statement**

476 Data file is available at synapse.org (<https://www.synapse.org/#!/Synapse:syn44590167>,
477 doi:10.7303/syn44590167)

478

479 **References**

- 480 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
481 real time. *The Lancet infectious diseases*. 2020;20(5):533-4.
- 482 2. Lhuillier E, Yang Y, Morozova O, Clouston SA, Yang X, Waszczuk MA, et al. The
483 Impact of World Trade Center Related Medical Conditions on the Severity of COVID-19
484 Disease and Its Long-Term Sequelae. *International Journal of Environmental Research and
485 Public Health*. 2022;19(12):6963.
- 486 3. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-
487 acute COVID-19 syndrome. *Nature medicine*. 2021;27(4):601-15.
- 488 4. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and
489 long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. *JAMA
490 network open*. 2021;4(10):e2128568-e.
- 491 5. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors
492 associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584(7821):430-6.
- 493 6. Ebinger JE, Achamallah N, Ji H, Claggett BL, Sun N, Botting P, et al. Pre-existing traits
494 associated with Covid-19 illness severity. *PLoS One*. 2020;15(7):e0236240.
- 495 7. Gao Yd, Ding M, Dong X, Zhang Jj, Kursat Azkur A, Azkur D, et al. Risk factors for
496 severe and critically ill COVID-19 patients: a review. *Allergy*. 2021;76(2):428-55.
- 497 8. Niemi ME, Daly MJ, Ganna A. The human genetic epidemiology of COVID-19. *Nature
498 Reviews Genetics*. 2022:1-14.
- 499 9. COVID-19 Host Genetics Initiative. The COVID-19 host genetics initiative, a global
500 initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-
501 CoV-2 virus pandemic. *European Journal of Human Genetics*. 2020;28(6):715.

- 502 10. Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, et
503 al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity
504 and mortality. *The Journal of clinical investigation*. 2021;131(23).
- 505 11. Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GH, Justice AE, et al.
506 Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and
507 yields risk scores associated with severe disease. *Nature genetics*. 2022;54(4):382-92.
- 508 12. Huang Q-M, Zhang P-D, Li Z-H, Zhou J-M, Liu D, Zhang X-R, et al. Genetic risk and
509 chronic obstructive pulmonary disease independently predict the risk of incident severe COVID-
510 19. *Annals of the American Thoracic Society*. 2022;19(1):58-65.
- 511 13. Crossfield SS, Chaddock NJ, Iles MM, Pujades-Rodriguez M, Morgan AW. Interplay
512 between demographic, clinical and polygenic risk factors for severe COVID-19. *International
513 Journal of Epidemiology*. 2022.
- 514 14. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of asthma and
515 its genetic predisposition with the risk of severe COVID-19. *Journal of Allergy and Clinical
516 Immunology*. 2020;146(2):327-9. e4.
- 517 15. Morozova O, Clouston SA, Valentine J, Newman A, Carr M, Luft BJ. COVID-19
518 cumulative incidence, asymptomatic infections, and fatality in Long Island, NY, January–August
519 2020: A cohort of World Trade Center responders. *PLoS One*. 2021;16(7):e0254713.
- 520 16. Waszczuk MA, Docherty AR, Shabalin AA, Miao J, Yang X, Kuan P-F, et al. Polygenic
521 prediction of PTSD trajectories in 9/11 responders. *Psychological Medicine*. 2020:1-9.
- 522 17. Huckins LM, Johnson JS, Cancelmo L, Diab O, Schaffer J, Cahn L, et al. Polygenic
523 regulation of PTSD severity and outcomes among World Trade Center responders. *medRxiv*.
524 2021:2020.12. 06.20244772.

- 525 18. Dasaro CR, Holden WL, Berman KD, Crane MA, Kaplan JR, Lucchini RG, et al. Cohort
526 Profile: World Trade Center Health Program General Responder Cohort. *International Journal of*
527 *Epidemiology*. 2015.
- 528 19. Cohen J. The cost of dichotomization. *Applied psychological measurement*.
529 1983;7(3):249-53.
- 530 20. MacCallum RC, Zhang S, Preacher KJ, Rucker DD. On the practice of dichotomization
531 of quantitative variables. *Psychological methods*. 2002;7(1):19.
- 532 21. McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A
533 reference panel of 64,976 haplotypes for genotype imputation. *Nature genetics*.
534 2016;48(10):1279.
- 535 22. Euesden J, Lewis CM, O'Reilly PF. PRSice: polygenic risk score software.
536 *Bioinformatics*. 2015;31(9):1466-8.
- 537 23. Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. Research
538 review: polygenic methods and their application to psychiatric traits. *Journal of Child*
539 *Psychology and Psychiatry*. 2014;55(10):1068-87.
- 540 24. Zhu Z, Lee PH, Chaffin MD, Chung W, Loh P-R, Lu Q, et al. A genome-wide cross-trait
541 analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic
542 diseases. *Nature genetics*. 2018;50(6):857-64.
- 543 25. Van Der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded
544 view on the genetic architecture of coronary artery disease. *Circulation research*.
545 2018;122(3):433-43.

- 546 26. Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association
547 analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes.
548 Nature communications. 2018;9(1):1-14.
- 549 27. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O'Connor GT, Wood RA, et al.
550 Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2.
551 Journal of Allergy and Clinical Immunology. 2020;146(1):203-6. e3.
- 552 28. Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, et al. Type 2
553 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway
554 epithelium. Nature communications. 2020;11(1):1-18.
- 555 29. Gil-Etayo FJ, Suárez-Fernández P, Cabrera-Marante O, Arroyo D, Garcinuño S, Naranjo
556 L, et al. T-helper cell subset response is a determining factor in COVID-19 progression.
557 Frontiers in cellular and infection microbiology. 2021;11:624483.
- 558 30. Zhu Z, Zhu X, Liu C-L, Shi H, Shen S, Yang Y, et al. Shared genetics of asthma and
559 mental health disorders: a large-scale genome-wide cross-trait analysis. Eur Respir J. 2019;54(6).
- 560 31. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al.
561 Association of obesity with disease severity among patients with coronavirus disease 2019.
562 Obesity. 2020;28(7):1200-4.
- 563 32. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA, Liang L. Association of obesity and
564 its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort
565 data. Metabolism. 2020;112:154345.
- 566 33. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of
567 COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252-60.

- 568 34. Mohammed I, Nauman A, Paul P, Ganesan S, Chen K-H, Jalil SMS, et al. The efficacy
569 and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and
570 mortality: A systematic review. *Hum Vaccin Immunother.* 2022;18(1):2027160.
- 571 35. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective.
572 *Immunological reviews.* 2011;242(1):10-30.
- 573 36. Zhu Z, Hasegawa K, Camargo Jr CA, Liang L. Investigating asthma heterogeneity
574 through shared and distinct genetics: Insights from genome-wide cross-trait analysis. *Journal of*
575 *Allergy and Clinical Immunology.* 2021;147(3):796-807.
- 576 37. Zhu Z, Guo Y, Shi H, Liu C-L, Panganiban RA, Chung W, et al. Shared genetic and
577 experimental links between obesity-related traits and asthma subtypes in UK Biobank. *Journal of*
578 *Allergy and Clinical Immunology.* 2020;145(2):537-49.

579

580

581 **Supporting Information**

582 **Table S1. Associations among PRS used in the study**

583 **Table S2. Descriptive statistics for participants of all ancestries**

584 **Table S3. Associations between allergic disease and asthma PRS and COVID-19 severity**
585 **and residual symptoms in participants of all ancestries**

586 **Table S4. Associations between coronary artery disease and type II diabetes PRS and**
587 **COVID-19 severity and residual symptoms in participants of all ancestries**

588 **Table S5. Associations between COVID-19 PRS and COVID-19 severity and residual**
589 **symptoms in participants of all ancestries**

590 **Table S6. Mental health and associations between COVID-19 outcomes and PRS for**
591 **asthma in European ancestry participants**